The Transcriptional Effects of MED1

Sp1 is a transcription factor that can regulate a variety of genes through direct binding to GC-rich areas of DNA and through interactions with other transcription factors including c-myc, c-Jun, and STAT11. Activation of Sp1 requires the activity of CRSP, or cofactor required for Sp1 activation, and one subunit of this protein is MED1, or mediator of RNA polymerase II transcription subunit 12. MED1 is the largest subunit in the CRSP complex and it can also be a part of the more ubiquitous Mediator complex, which activates RNA polymerase II transcription of a wide range of gene targets throughout the genome. Phosphorylation of MED1 appears to support its inclusion in the Mediator complex3. MED1 is furthermore the component of the Mediator complex that targets this complex to nuclear hormone receptors4. MED1 may be referred to by several other names including CRSP1, TRAP220, CRSP200, and PBP.

MED1 regulates transcription downstream of several signaling pathways, including estrogen receptor signaling via interactions with CCAR15, thyroid hormone receptor, and the vitamin D receptor6. Phosphorylation of MED1 by ERK appears to augment the downstream effects of signaling through the thyroid hormone receptor7 and the vitamin D receptor8. Activation of Sp1 requires interaction between CRSP and transcription factors of the TFII family, notably TFIID. While Sp1 is a transcriptional enhancer, CRSP and TFIID form the transcription factor complex necessary to recruit Sp1 to the gene site2,9.

The transcriptional effects of MED1 play a key part in many different cell types and organ systems throughout the body. MED1-mediated transcription in bone marrow stromal cells helps to maintain hematopoietic stem cells in that niche by regulating the expression of osteopontin downstream of vitamin D receptor signaling10. MED1 is also expressed by keratinocytes in the skin, where it promotes the maintenance of hair growth11. MED1 has been reported to play diverse roles in cancer progression. In non-small cell lung cancer, loss of MED1 promotes cancer metastasis12 and in invasive bladder cancer, MED1 expression was reported to be decreased and low MED1 expression was associated with decreased survival13. A similar effect was observed in melanoma, where low levels of expression of MED1 was associated with an invasive phenotype14. In breast cancer, MED1 functions in crosstalk between the estrogen and HER2 receptors, and MED1 expression promotes resistance to tamoxifen therapy15. MED1 also plays a role in regulating metabolism, and loss of MED1 promoted mitochondrial biogenesis and a shift towards oxidative phosphorylation16. Thus, transcription mediated by MED1 complexes plays diverse roles in organ systems throughout the body and has different effects depending on the upstream signaling pathway and cell type controlling its expression.


1. Tan NY, Khachigian LM (2009) Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 29:2483–8 . doi: 10.1128/MCB.01828-08

2. Ryu S, Zhou S, Ladurner AG, Tjian R (1999) The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature 397:446–450 . doi: 10.1038/17141

3. Taatjes DJ (2010) The human Mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci 35:315–22 . doi: 10.1016/j.tibs.2010.02.004

4. Belakavadi M, Fondell JD (2006) Role of the mediator complex in nuclear hormone receptor signaling. Rev Physiol Biochem Pharmacol 156:23–43

5. Kim JH, Yang CK, Heo K, et al (2008) CCAR1, a Key Regulator of Mediator Complex Recruitment to Nuclear Receptor Transcription Complexes. Mol Cell 31:510–519 . doi: 10.1016/j.molcel.2008.08.001

6. Taatjes DJ, Schneider-Poetsch T, Tjian R (2004) Distinct conformational states of nuclear receptor–bound CRSP–Med complexes. Nat Struct Mol Biol 11:664–671 . doi: 10.1038/nsmb789

7. Pandey PK, Udayakumar TS, Lin X, et al (2005) Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Mol Cell Biol 25:10695–710 . doi: 10.1128/MCB.25.24.10695-10710.2005

8. Cui M, Zhao Y, Hance KW, et al (2009) Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2. J Cell Physiol 219:132–142 . doi: 10.1002/jcp.21657

9. Ryu S, Tjian R (1999) Purification of transcription cofactor complex CRSP. Proc Natl Acad Sci U S A 96:7137–42

10. Ryu S, Tjian R (1999) Purification of transcription cofactor complex CRSP. Proc Natl Acad Sci U S A 96:7137–42

11. Nakajima T, Inui S, Fushimi T, et al (2013) Roles of MED1 in Quiescence of Hair Follicle Stem Cells and Maintenance of Normal Hair Cycling. J Invest Dermatol 133:354–360 . doi: 10.1038/JID.2012.293

12. Kim H-J, Roh MS, Son CH, et al (2012) Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes. Cancer Lett 321:195–202 . doi: 10.1016/J.CANLET.2012.02.009

13. Klümper N, Syring I, Vogel W, et al (2017) Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. Front Med 4:30 . doi: 10.3389/fmed.2017.00030

14. Ndong J de LC, Jean D, Rousselet N, Frade R (2009) Down-regulation of the expression of RB18A/MED1, a cofactor of transcription, triggers strong tumorigenic phenotype of human melanoma cells. Int J Cancer 124:2597–2606 . doi: 10.1002/ijc.24253

15. Cui J, Germer K, Wu T, et al (2012) Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells. Cancer Res 72:5625–5634 . doi: 10.1158/0008-5472.CAN-12-1305

16. Yu J, Xiao Y, Liu J, et al (2014) Loss of MED1 triggers mitochondrial biogenesis in C2C12 cells. Mitochondrion 14:18–25 . doi: 10.1016/J.MITO.2013.12.004